S. Harding

发表

Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the Canadian Scleroderma Research Group registry

M. Baron, J. Pope, A. Bonner, 2011, Arthritis care & research.

Calcium channel blockers for primary and secondary Raynaud's phenomenon.

P. Tugwell, G. Wells, L. Maxwell, 2017, The Cochrane database of systematic reviews.

Association of C‐reactive protein with high disease activity in systemic sclerosis: Results from the Canadian Scleroderma Research Group

M. Baron, J. Pope, C. Muangchan, 2012, Arthritis care & research.

Best practices in scleroderma: an analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG).

M. Baron, J. Pope, A. Bonner, 2012, Clinical and experimental rheumatology.

Drug interventions versus placebo for the treatment of Raynaud’s phenomenon: generic protocol

P. Tugwell, G. Wells, L. Maxwell, 2015, Cochrane Database of Systematic Reviews.

THU0249 C - reactive protein (CRP) is associated with high disease activity in SSC and ILD. Results from the canadian scleroderma research group (CSRG)

M. Baron, J. Pope, A. Bonner, 2013 .

Agreement with Guidelines from a Large Database for Management of Systemic Sclerosis: Results from the Canadian Scleroderma Research Group

M. Baron, J. Pope, A. Bonner, 2012, The Journal of Rheumatology.

Cyclofenil for Raynaud's phenomenon in progressive systemic sclerosis.

A. Silman, B. Shea, D. Furst, 1998, The Cochrane database of systematic reviews.

Prazosin for Raynaud's phenomenon in progressive systemic sclerosis.

A. Silman, B. Shea, D. Furst, 1998, The Cochrane database of systematic reviews.

Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon.

L. Maxwell, Elizabeth Tanjong Ghogomu, P. Tugwell, 2023, The Cochrane database of systematic reviews.